List of Studies ( Metabolite:Eicosadienoyl-EA)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001680 | AN002740 | Metabolome of NAFLD in high fat diet mouse model | Liver | Mouse | Fatty liver disease | Weill Cornell Medicine | Abundance |
ST001795 | AN002915 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) | Mesenteric lymph | Mouse | Obesity | Monash Institute of Pharmaceutical Sciences | height |
ST001796 | AN002917 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib | Mesenteric lymph | Mus musculus | Diabetes | Monash Institute of Pharmaceutical Sciences | height |
ST001788 | AN002899 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST002182 | AN003574 | Amelioration of developmental programming of NAFLD in weanling liver using PQQ | Liver | Mouse | Fatty liver disease | University of Oklahoma Health Sciences Center | Peak area |
ST002191 | AN003586 | Amelioration of developmental programming of NAFLD in fetal liver using PQQ | Liver | Mouse | Fatty liver disease | University of Oklahoma Health Sciences Center | Peak area |
ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST001275 | AN002116 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000551 | AN000842 | Investigating large scale metabolomics in mice tissue lacking insulin receptors and IGF-1 receptors | Muscle | Mouse | Diabetes | Mayo Clinic | Peak intensity |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |